Navigation Links
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Date:5/26/2008

Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Newer antipsychotic drugs (olanzapine, quetiapine fumarate and risperidone) have been on the market for more than a decade and are commonly used to treat the behavioral and psychological symptoms of dementia, the authors write as background information in the article. Antipsychotic drugs are often used for short periods to treat agitation in clinical practice. They are frequently prescribed around the time of nursing home admission. About 17 percent of individuals admitted to nursing homes are starting on antipsychotic medication within 100 days, and 10 percent receive only a single prescription. Given the widespread use of short-term prescriptions, it is important to evaluate their safety, the authors note.

Paula A. Rochon, M.D., M.P.H., F.R.C.P.C., of the Institute for Clinical Evaluative Sciences (ICES), Ontario, and colleagues studied older adults with dementia living in the community or in nursing homes between 1997 and 2004. In each setting, the researchers identified three groups of equal size who were identical except for their exposure to antipsychotic medications. Among 20,682 older adults with dementia living in the community, 6,894 did not receive antipsychotics, 6,894 were prescribed atypical or newer antipsychotics and 6,894 were prescribed conventional antipsychotics, such as haloperidol or loxaprine. Among 20,559 older adults with dementia living in nursing homes, 6,853 received no antipsychotics, 6,853 received atypical antipsychotics and 6,853 received conventional antipsychotics.

Participants medical records were examined for serious adverse events, defined as hospital admissions and death within 30 days of beginning therapy. Relative to community-dwelling older adults with dementia who did not receive a prescription for antipsychotic drugs, similar older adults who did receive atypical antipsychotic drugs were three times more likely and those who received a conventional antipsychotic drug were almost four times more likely to experience a serious adverse event within 30 days of starting therapy, the authors write. Relative to nursing home residents in the control group, individuals in the conventional antipsychotic therapy group were 2.4 times more likely to experience a serious adverse event leading to an acute care hospital admission or death. Those in the atypical antipsychotic group were 1.9 times more likely to experience a serious adverse event during 30 days of follow-up.

The analysis may underestimate the number of adverse events because of the short length of follow-up, the authors note. In addition, physicians who notice early signs of a problem may take patients off antipsychotics, avoiding more serious consequences, and many serious events experienced by nursing home residents are dealt with in the facility without hospital admission. Our results exploring serious adverse events likely identify only the tip of the iceberg, they write. Antipsychotic drugs should be prescribed with caution even for short-term therapy.


'/>"/>

Contact: Kristine Galka
416-480-4780
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Physiotherapy has short-term benefits for patients after knee surgery
2. Short-term hemofiltration is cost-effective for severe acute pancreatitis
3. The Westaim Corporation update on status of short-term investments
4. Journal Sleep: A short-term dose of zolpidem is an effective treatment for insomnia
5. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
6. Antidepressant as Good as Antipsychotics for Dementia
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. Many Older Americans Have Active Sex Lives
9. Good Cholesterol Wont Help Heavy-Drinking Older Men
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay Southerland ... version at the International Roofing Expo in Orlando, Florida on February 17-19. , ... advanced weather technology in the hands of consumers, roofing contractors, manufacturers and distributors,” ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast Therapeutics, ... novel, clinical-stage therapies for sickle cell disease and heart ... offering of 29,090,910 units at a price to the ... one share of the Company,s common stock and one ... stock at an exercise price of $0.42 per share. ...
(Date:2/10/2016)... 10, 2016 /PRNewswire/ - The President of New Venture ... release of an anti-radiation product from their Research ... in the treatment of cancer using radiation and ... assist in the healing of radiation burns, even ... protect only the healthy cells from radiation damage. ...
Breaking Medicine Technology: